

ELENICE STROPARO

**HIV/AIDS+ PATIENTS TREATED WITH THE HOMEOPATHIC MEDICINE CANOVA:
PROSPECTIVE OBSERVATIONAL STUDY IN LABORATORY, CLINICAL AND OF QUALITY
OF LIFE INDEXES.**

Summary of Dissertation presented to the Post-Graduation program in Cellular and Molecular Biology of the Biological Sector of Federal University of Parana, for obtaining the title of Master in Molecular and Cellular Biology.

Oriented by: Prof^a. Dr^a. Dorly de Freitas Buchi.

CURITIBA

2005

1. RESULTS AND DISCUSSION

All the 43 patients were divided into two groups: the ones using antiretrovirals and the ones that did not make use of these medicaments, however the results are presented without the group division, since the results obtained are similar.

1.1 SAMPLE DESCRIPTION

The majority of the patients was, in general, well. The research had the cooperation of 43 patients, being 25 males and 18 females.

The group was composed by people who had acquired the HIV virus through blood transfusion, by using injectable drugs or in sexual intercourse. The research has the participation of heterosexuals, homosexuals and bisexuals.

The evaluated group was constituted by 11 patients who made use only of alternative treatments, such as florals, homeopathy, massages, meditation among others, and by 32 patients that, besides those, made use of conventional medication (antiretrovirals).

About the results, we should point out that the questionnaire questions got grades from zero to ten, being zero the worst condition (a lot of pain, exhaustion, etc.) and ten the best condition (absence of pain, vitality, etc.), and the laboratorial results of T1 and T6 were compared to the results obtained in T0 (before taking the homeopathic medicament Canova).

1.2 QUESTIONNAIRE ANALYSIS – RESULTS AND DISCUSSION

All data was graded and analyzed statistically, but only in **Energy, Depression, Pain** and **Appetite** the differences were significant. Relating to – **Energy** and **Depression** we obtained $p < 0,01$ (**). In the variables - **Pain** and **Appetite** $p < 0,05$ (*). But relating to – **General Health, Attention** and **Well-Being**, in spite of the graphics showing a tendency to improvement, still the evolution of these variables did not result in statistically different. The variables above, for being continuous, were submitted to ANOVA and, when the averages were different, to Tukey.

Affective Life, Food Preferences and **Sleep Quality** – were tested through the χ^2 test, for being independent variables.

1.3 OPPORTUNISTIC INFECTIONS AND LABORATORIAL DATA


All data was graded and analyzed statistically, but only in **Opportunistic Infections, Weight, Number of Erythrocytes** and **CD4 Account** the differences were significant. Relating to **Number of Erythrocytes** and **CD4 Account**, we obtained $p < 0,05$ (**) and relating to the variable – **Weight** we obtained $p < 0,01$ (**). But relating to **Hb, HCT, Total Number of Leukocytes, CD8** and **Viral Load**, in spite of the graphics showing a tendency to improvement, still the evolution of these variables did not

result in statistically different. The variables above, for being continuous, were submitted to ANOVA and, when the averages were different, to Tukey.


Opportunistic Infections, relating to the different Times, was tested through the χ^2 test, for being an independent variable. The difference found was statistically significant.

1.3.1 CD4/CD8

Concerning CD4 the graphic 12 shows that in T0 the average found was 419,08 and in T6 the average found moved to 469,91. We can realize that the period of treatment with the Homeopathic Medicament Canova was significant ($p < 0,05$).




The difference found in the CD8 value of Time Zero and after 6 months of treatment with the Homeopathic Medicament Canova, was not significant. The CD4/CD8 relation improved, in spite of the CD8 numbers not being statistically different. The increase in CD4 cells can also be, in part, responsible for the decrease of opportunistic diseases during the treatment with the Homeopathic Medicament Canova.



1.3.2 Viral Load




In graphic 14 we can verify that the average related to the viral load variable in T0 was of 62830 and to T6 31523, indicating a general reduction of almost 50%.





1.3.3 Electronic Microscopy of Transmission

The blood of 3 patients using ARV with elevated viral load was processed through the electronic microscopy of transmission in Time 0. After 1 month of treatment, there was a new blood collect of these patients, which were submitted to the same procedure. The images were obtained in the electronic microscope of transmission Jeol 1200 EXII attached to a digital system of images of Gatan, from the Center of Electronic Microscopy of UFPR.

We can observe in images 1A, B, C e D, before the beginning of the treatment with the Canova medicament, an electro-dense in the plasmatic membrane, suggestive of the budding of the virus (arrows). It is important to emphasize that this kind of formation only appears in the blood evaluated in Time 0. In the blood collected after 30 days of treatment, besides not being able to see anymore the electro-dense regions, there can be observed the presence of great cells with the morphology of activated cells: great striped nucleolus, evident nuclear pores, many euchromatin, cytoplasm rich in mitochondria, free ribosome, and polyribosome.



Pictures 1A, 1B, 1C and 1D: Electronic Microscopy of Transmission - Budding – Images 1A, 1B, 1C and 1D show different cells with electron-dense formation (arrows) suggestive of virus budding areas in Time 0.




Pictures 2A e 2B: Electronic Microscopy of Transmission – Characteristics of Activated Cells – The images 2A and B show the cell with morphology of activated cell, nucleus (N) rich in euchromatin and evident nuclear pores (P), mitochondria (M) e polyribosome (arrows). This kind of cell was found only in the blood of patients after using Canova.

2. NON-SIGNIFICANT VARIABLES OF RESULT

Measurement Group Questionnaire: Despite the data show a tendency to improvement, still the evolution of **Affective Life, Food Preferences** and **Sleep Quality** did not result in statistically different. For these variables, it was made an individual account, that is, how many patients presented or not certain symptom.

In graphic 15 we have a general view of several symptoms evaluated during the first month of accompanying of patients using Canova. It was evaluated the presence or not of: 1) abdominal pain and/or diarrhea; 2) general pain; 3) dermatitis; 4) breathing problems; and 5) patients that did not present any of these symptoms.



Laboratorial Data: Despite the data show a tendency to improvement, still the evolution of **Hemoglobin (Hb), Hematocrit (HCT) e Total Number of Leucocytes**, did not result in statistically different.

3. CONCLUSION

The Homeopathic Medicament Canova, according to the study, can be considered as one more option to the treatment of seropositivity, presenting lower cost than conventional medicines, and relieving pain and discomfort.

All the patients who participated in the study group obtained a significant improvement during the treatment.

Therefore, one can conclude that, after 6 months of treatment with the Homeopathic Medicament Canova, HIV/AIDS+ patients, using or not conventional medicines, improved in the following parameters:

- Increase of appetite and available energy for routine tasks;

- Decrease of pain and depression;
- Decrease of opportunistic infections;
- Increase in the number of Lymphocytes CD4 and total number of Erythrocytes;

And, finally,

- Increase in the Life Quality of bearers of HIV/AIDS.

4. REFERÊNCIAS

1999 USPHS/IDSA **guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus**. U.S. Public Health Service (USPHS) and Infections Diseases Society of America (IDSA) U.S. Public Health Service (USPHS) and Infections Diseases Society of America (IDSA). MMWR Morb Mortal Wkly Resp 1999; 48 (RR-10): 1-59, 61-6.

ABBAS, A K.; LICHTMAN, A H.; POBER, J.S. **Celular and Molecular Immunology**. 2.ed. Philadelphia: W.B. Saunders Company, 1994. p. 12, 16, 19, 20, 269 and 276.

ALBERTS, B., *et al.* **Biologia Molecular da Célula**, Terceira ed., Artes Médicas. SP 1997, p. 139, 152, 1162 – 1164 e 1169.

American Dietetic Association (ADA). **Nutrition intervention in the care of persons with human deficiency virus infection** – Position of the American Dietetic Association and Dietian of Canada. J. Am. Diet Assoc. 2000; 100: 708 – 17.

ANDERSON, R.G.W. **The Caveolae Membrane System**. Annu. Rev. Biochem. 1998. 67:199-225.

BALLOW, M; NELSON, R. **Immunopharmacology – Immunomodulation and Immunotherapy**. JAMA, Chicago. V. 278, nº 2, p. 2008 – 2017, 1997.

BAUER, M. E. **Estresse-Como ele abala as defesas do corpo?** Revista: Ciência Hoje, 2002. Vol 30, Nº 179, p. 21-25.

BERNER, L.C. Disponível em: <http://www.pnl_uptime.med.br/fadiga.html> Acesso em: 10 de Mar. de 2005.

BORROW, P.; *et al.* **Antiviral pressure exerted by HIV-1 specific cytotoxic T-lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus**. Nat Med 1997; 3:205-11.

BREEN, E.C. **Pro- and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome**, *Pharmacology & Therapeutics* 2002; 95: 295-304.

BUENO, F. da S. **Dicionário Escolar de Língua Portuguesa**; 11^a ed., RJ 1983. p. 1078.

CANOVA DO BRASIL. Disponível em: <<http://www.canovado brasil.com.br>> Acesso em: 27 de Dez. de 2004.

CAPURON, L.; *et al.* **Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy**. *Mol Psychiat* 2002; 7: 468-473.

CC 530/550 – **Contador de Células. Manual de Operação**. Marca de Fabricação: CELM (Companhia Equipadora de Laboratórios Modernos). – Alphaville, SP. Registro no M.S. Número 10125310048.

CIVIN, C. I.; LOKEN, M. R. **Cell surface antigens on human marrow cells: dissection of hematopoietic development using monoclonal antibodies and multiparameter flow cytometry**. *International Journal of Cell Cloning*. Vol. 5. p. 267-288. 1987.

CHINEN, J; SHEARER, W.T. **Basic and Clinical Immunology**, *Journal of Allergy and Clinical Immunology*, 2003; 111:5813 –5818.

CHINEN, J. ; SHEARER, W.T. **Molecular virology and immunology of HIV infection**, *Journal of Allergy and Clinical Immunology* 2002; 110:189 –198.

CLERICI, M., *et al.* **Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection**. *AIDS Res Hum Retroviruses* 1996; 12:1053-61.

CONTI, L., *et al.* **Immunomodulatory effects of the HIV-1 gp120 protein on antigen presenting cells: implications for AIDS pathogenesis**. *Immunobiology* 2004; 209:99-115.

COTRAN, R.S.; KUMAR, V.; ROBBINS,S.L. **Patologia estrutural e funcional**. Guanabara Koogan, Quarta ed., Rio de Janeiro 1989, p. 137-139, 191, 542-543.

CUELLAR, M.L. **HIV infection-associated inflammatory musculoskeletal disorders**. *Rheumatic Disease Clinics of North American* 1998; 24: 403-421.

- DARKO, D.F.; *et al.* **Fatigue, sleep disturbance, disability, and indices of progression of HIV infection.** Am. J. Psychiatry 1992; 149: 514-20.
- DAVIDHZAR, R.; DUNN, C. **Nutrition and the client with AIDS.** J. Pract Nurs. 1998; 48: 16-25.
- Di ROCCO, A.; SIMPSON, D.M. **AIDS – associated vacuolar myelopathy.** AIDS Patient Care STDS 1998; 12 (6): 457-61.
- DWIER, J.T.; *et al.* **The use of unconventional remedies among HIV-positive men living in California.** J Assoc. Nurses AIDS Care 1995; 6: 17-28.
- ELEOPULOS, E.P.; *et al.* **A critique of the Montagnier evidence for the HIV/AIDS hypothesis.** Medical Hypotheses 2004; 63: 597-601.
- ELSE, K.J. **Chemokines and leucocyte migration in parasitic disease.** Parasite Immunology 2002; 24: 281-283.
- EVANS, D.L.; *et al.* **Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection.** Am. J. Psychiatry 2002; 159: 1752-1759.
- FAILACE, R. **Hemograma – Manual de Interpretação.** Artes Médicas. Porto Alegre 1995, p. 18, 23-24, 27, 30, 46, 111 e 116.
- FAUCI, A. **The AIDS epidemic.** Considerations for the 21^a century. N.Engl. J. Med. 1999; 341: 1046-1050.
- FERREIRA, V. M. B. Disponível em: <http://www.hiv.org.br/internas_materia.asp? > Acesso em: 10 de Jan. de 2005.
- FIGUEIRAL, M. Disponível em: <http://www.universiabrasil.net/materia_imp.jsp?id=4659> Acesso em: 09 de Nov. de 2004.
- FOSTER, H. D. **How HIV-1 causes AIDS: implications for prevention and treatment.** Medical hypotheses 2004; 62: 549-553.

- FUJITA, Y.; *et al.* **Leptin inhibits stress-induced apoptosis of T lymphocytes.** Clin Exp Immunol 2002; 128(1): 21-6.
- GOGU, S.R.; BECKMAN, B.S.; WILSON, R.B.; AGRAWAL, K.C. **Inhibitory effects of zidovudine in erythroid progenitor cells. Reversal with a combination of erythropoietin and interleukin-3.** Biochem Pharmacol 1995; 50: 413-419.
- GREMBERG, P.D. **Mechanism of tumor immunology.** In: STITES, D.P.; TERR, A I.; PARSLAW, T.G. Basic & Clinical Immunology. 8 ed. London: Printice-Hall International Inc., 1994. P 567 – 577.
- GROOPMAN, J.E. **Fatigue in cancer and HIV/AIDS.** Oncology 1998; 12: 335-344.
- GRUPO GEROLIMICH. Disponível em:
<<http://www.gerolimich.hpg.ig.com.br/especial/aids08.htm>> Acesso em: 10 de Jan. de 2005.
- GUDER, W.G.; NARAYANAN, S.; WISSER, H.; ZAWTA, B. **Coleta de Amostras: do paciente para o laboratório: o impacto das variáveis pré-analíticas sobre a qualidade dos resultados de laboratório,** SP 1996. Tradução de Maria José Pontieri.
- HART, J.D.; SIGNORI, P. **AIDS,** Editora Saúde, sem página, 1998.
- HAVENS, P.L. **Principles of antiretroviral Treatment of children and adolescents with Human Immunodeficiency virus Infection.** Elsevier 2003; 14: 269-285.
- HEMONLINE. Disponível em: <<http://www.hemonline.com.br/aids.htm>> Acesso em: 07 de Jan. de 2005.
- JACOLS, R.; HEIBEN, H.; SCHIMIDT, R.E. **Mutual interference of HIV and Natural Killer cell-mediated immune response.** Molecular Immunology 2005; 45: 239-249.
- JANEWAY, C.A; TRAVERS, P. **Immuno Biology – The immune system in health and disease.** CB 3.ed. 1997; p. 1:2 - 7:27.
- JONAS, W.B.; JACOBS, J. **A cura através da homeopatia,** Rio de Janeiro, Editora Campus, 1996.

- JUNQUEIRA, L.C.; CARNEIRO, J. **Biologia Celular e Molecular**. Guanabara Koogan, 5ª ed., SP 1991. p. 22 e 27
- KRISTIANSEN, T.B.; KNUDSEN, T.B.; EUGEN-ONLSEN, J. **Chemokine receptors and their crucial role in human immunodeficiency virus infections: major breakthroughs in HIV research**. Scand J. Immunol, 1998; 48:339-46.
- KROP, I. *et al.* **The signaling activity of murine CD19 is regulated during B cell development**. J. Immunol. 1996; 157: 48-56.
- LAI, L.; ALAVERDI, N.; MALTAIS, L.; MORSE III, H.C. **Mouse cell surface antigens: nomenclature and immunophenotyping**. J. Immunol., V. 160, nº 8, p.3861 – 8, 1998.
- LEE, G.R.; *et al.* **Wintrobe's Clinical Hematology**. 10 th ed. Lippincott Williams & Wilkins. Volume 1 and 2; 1999. p. 1957-1958.
- LOPES, L.; GODOY, L. M. F.; OLIVEIRA de, C. C.; GABARDO, J; SCHADECK, R. J. G.; BUCHI, D.F. **Phagocytosis, Endosomal/Lysosomal System and other Cellular Aspects of Macrophage Activation By Canova medication**. 2004. Rev. Micron (in press).
- MAES, M. **Evidence for an immune response in major depression: A review and hypothesis**. Prog Neuropsychopharmacol, Biol Psychiat 1995; 19: 11-38.
- MARÉCHAL, V. ; *et al.* **Human Immunodeficiency Virus Type 1 Entry into Macrophages Mediated by Macropinocytosis**. Journal of Virology 2001; 11166-11177.
- MC CUNE, J. **The dynamics of CD4 T-cell depletion in HIV disease**. Nature 2001; 410: 974 –9.
- MC MICHAEL, A J.; ROWLAND-JONES, S.L. **Cellular Immune responses to HIV**. Nature 2001; 10: 980 – 7.
- MOYLE, G.; *et al.* **Changes in Hematologic Parameters and Efficacy of Thymidine Analogue – Based, Highly Active Antiretroviral Therapy: A meta-Analysis of Six Prospective, Randomized, Comparative Studies**. Excerpta Medica 2004; 26: 92-97.
- MOORE, R.D., CHAISSON, R.E. **Natural history of HIV infection in the era of combination antiretroviral therapy**. AIDS 1999; 13: 1933-42.

OFORI, H.; PROKOP, J.; JAGODZINSKI, P.P. **Replication at the level of reverse transcription of HIV-1SF2 strain in Th1 and Th2 cells.** Biomedecine & Pharmacotherapy 2002; p. 1-5.

PANTALEO, G.; *et al.* **The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia.** Proc Natl Acad Sci USA 1997; 94: 254 – 8.

PARKIN, J.; COHEN, B. **An overview of the immune system,** *The Lancet* 2001; 357: 1777-1789.

PIEMONTE, M.R.; BUCHI, D.F. – **“Analyses of Il-2, IFN γ and TNF α production, α 5, β 1 integrins and actin filament distribution in peritoneal mouse macrophages treated with an homeopathic medicament”**, J. Submicro.Cytol.Pathol., in press, v. 33, n. 4, 2001.

POLACOW, V.O. *et al.* **Alterações do estado nutricional e dietoterapia na infecção por HIV.** Rev. Bras. Nutr. Clin. 2004; 19(2):79-85.

PORTAL DA COLUNA. Disponível em: <<http://www.portaldacoluna.com.br/conteudo.asp>> Acesso em: 10 de Jan. de 2005.

PROGRAMA NACIONAL DE DST E AIDS - ASSISTENCIA. Disponível em: <http://www.aids.gov.br/assistencia/etiologia_diagnostico.htm> Acesso em: 29 de Dez. 2004.

PROGRAMA NACIONAL DE DST E AIDS – MANUAL DST. Disponível em: <<http://www.aids.gov.br/assistencia/manualdst/item12.htm>> Acesso em: 07 de Jan. de 2005.

PROGRAMA NACIONAL DE DST E AIDS - TRATAMENTO. Disponível em: <<http://www.aids.gov.br/final/tratamento/adulto.pdf>> Acesso em: 30 de Dez. de 2004.

PROGRAMA NACIONAL DE DST E AIDS - LIVRO. Disponível em: <<http://www.aids.gov.br/livro/>> Acesso em: 29 de Dez. de 2004.

PROJINF. Disponível em: <<http://www.projinf.org/>> Acesso em: 10 de Mar. de 2005.

QUINN, T.C. **Acute primary HIV infection.** JAMA 1997; 278: 58 – 62.

RAAPHORST, F.M. *et al.* **TCRBV CDR3 Diversity of CD4+ and CD8+ T-Lymphocytes in HIV-Infected Individuals**, Human Immunology 2002; 63: 51-60.

RACHID, M.; SCHECHTER, M. **Manual de HIV AIDS**. Rio de Janeiro: Revinter, 2000.

REPETTO, M. *et al.* **Oxidative stress in blood of HIV infected patients**, Clinica Chimica Acta 1996, 255: 107-117.

RODRIGUEZ, C.; THOMAS, J.K.; O'ROUKE, S.; STIEHM, E.R.; PLAEGER, S. **HIV disease in children is associated with a selective decrease in CD23 and CD62L B-cells**. Clin Immunol. Immunopathol 1996; 81: 191 – 9.

ROITT, I.; BROSTOFF, J.; MALE, D. **Imunologia**, 6.ed. SP: Marole 2003, p. 481.

ROMAGNANI, S.; *et al.* **Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells**. Science 1994; 265: 244 – 8.

RUBINSTEIN, M.L., SELWYN, P.A. **High prevalence of insomnia in na out-patient population with HIV infection**. J. Acquir Immune Defic Syndr Hum Retrovirol 1998; 19 (3): 260-5.

SASAKI, M.G.M; MARIANO, F.C.; GURGEL, L.P.; PROBST, S. **Estudo Clínico randomizado placebo controlado para avaliar a eficácia e segurança do Método Canova na terapêutica de pacientes portadores de HIV/AIDS em uso de anti-retrovirais**. J Infectious Diseases, v. 5, supplement 1, p. 58, 2001.

SATO, S.; MILLER, A S.; HOWARD, M.C.; TEDDER, T.F. **Regulation of B lymphocyte development and activation by the CD19/CD21/CD81 Leu 13 Complex requires the cytoplasmic domain of CD19**. J. Immunol., v 159, p 3278 – 87, 2002.

SCCADDEN, D.T. **Stem cells and immune reconstitution in AIDS**, Blood Reviews 2003, 17: 227-231.

SCHACKER, T.; COLLIER, A C.; HUGHES, J.; SHEA, T.; COREY, L. **Clinical and epidemiologic features of primary HIV infection**. Ann Intern Med. 1996; 125: 257 – 64.

SCHAEFFER, E.; GELEZIUNAS, R.; GREENE, W.C. **Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions.** J virol 2001; 75: 2993 – 3000.

SEPULVEDA, R. T.; WATSON, R.R. **Treatment of antioxidant deficiencies in AIDS patients.** Nutrition Research 2002; 22: 27-37.

SHERMAN, M.P.; GREENE, W.C. **Slipping through the door: HIV entry into the nucleus.** Microbes and Infection 2002; 4: 67 – 63.

SILVA, P.H. da; HASHIMOTO, Y. **Interpretação Laboratorial do Eritrograma.** Texto & Atlas. Editora Lovise Ltda. São Paulo 1999. p. 33 e 59.

SINATEC I – **I Simpósio Nacional de Terapia Celular** – de 03 a 05 de Junho de 2005. Hotel Sheraton Four Points. Curitiba-PR – Professor Doutor Ricardo Ribeiro dos Santos (FIOCRUZ/Ba/Instituto do Milênio/CNPq).

SLEASMAN, J.W.; GOODNOW, M.M. **HIV-1 Infection**, Journal of Allergy and Clinical Immunology 2003; 111: 582 – 592.

SOUZA, W.; *et al.* **Técnica Básicas de Microscopia Eletrônica Aplicadas às Ciências Biológicas.** Editor: Wanderley de Souza. Rio de Janeiro: Sociedade Brasileira de Microscopia, 1998. Pag. 18-19, 22 e 27.

SPIGA, M.G.; WEIDNER, D.A; TRENTESAUX, C.; *et al.* **Inhibition of beta-globin gene expression by 3'-azido-3'- deoxythymidine in human erytroid progenitor cells.** Antiviral Res. 1999; 44: 167-177.

STITES, D.P. **Imunologia**, Rio de Janeiro 1992, Brasil.

TANAKA, M.; *et al.* **Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1**, Virology 2003:1-10.

TEIXEIRA, M.Z. **Esclarecendo a Homeopatia.** Disponível em: <[http://www. homeozulian.med.br/](http://www.homeozulian.med.br/)> Acesso em: 14 de Dez. de 2004.

TEIXEIRA, M.Z. **Panorama da Pesquisa em homeopatia: iniciativas, dificuldades e propostas.**

Disponível em: <<http://www.amhb.org.br/nuke/>> Acesso em 14 de Dez. de 2004.

THAN, S.; *et al.* **Cytokine pattern in relation to disease progression in human immunodeficiency virus-infected children.** J Infect. Dis 1997; 175: 47 – 56.

UNICEF. Disponível em: <http://www.unicef.pt/18/breve_nota_unicef-1dez04.pdf> Acesso em: 29 de Dez. de 2004.

VERANI, A; GRAS, G.; PANCINO, G. **Macrophages and HIV-1: dangerous liaisons.** Molecular Immunology 2004; 1 – 17.

VERGIS, E.N.; MELLORS, J.W. **Natural history of HIV-1 infection.** Infect Dis Clin North Am 2000; 14: 809 – 25 v – vi.

WHITE, J.L.; *et al.* **Early central nervous system response to HIV infection: sleep distortion and cognitive – motor impairment.** AIDS 1995; 9 (9): 1043-50.

WHOQOL GROUP. Disponível em: <<http://www.ufrgs.br/psiq/whoqol.html>> Acesso em: 07 de Ago. de 2005.

YUN, A J.; LEE, P.Y.; BAZAR, K.A . **Modulation of host immunity by HIV may be partly achieved through usurping host autonomic functions.** Medical Hypotheses 2004; 1 – 5.

ZAGO, M.A; FALCÃO, R.P.; PASQUINI, R. **Hematologia: Fundamentos e Prática.** Editora Atheneu. São Paulo 2001. p. 7, 27-28, 104 e 705.

ZHANG, L. *et al.* **Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.** N Engl J. Med 1999; 340: 1605-13.

ZHANG, Z.; SCHULER, T.; ZUPANCIC, M.; WIETGREFE, S.; *et al.* **Sexual transmission and propagation of SIV HIV in resting and activated CD4+ T cells.** Science 1999; 286: 1353 – 57.